Skip to main content
SpringerLink
Log in

Gadolinium Retention in Brain and Body: Clinical and Preclinical Evidence

  • Chapter
  • First Online:
Imaging in Nephrology

Abstract

Appropriate use of gadolinium-based contrast agents (GBCAs) in contrast-enhanced MRI is indicated for morphologic imaging, lesion characterization, perfusion imaging, and contrast-enhanced angiography [1]. The added diagnostic value of GBCAs consists of (a) increasing differences of T1, T2, and T2* relaxation time constants between different tissues or normal and pathologic tissues; (b) increasing overall MRI sensitivity; (c) increasing MRI diagnostic specificity by allowing evaluation of different patterns of enhancement and perfusion of differently vascularized tissues; and (d) increasing contrast between intra- and extravascular space in cardiac and vascular imaging.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kanal E, Maravilla K, Rowley HA. Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. AJNR Am J Neuroradiol. 2014;35(12):2215–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Lancelot E. Revisiting the pharmacokinetic profiles of gadolinium-based contrast agents: differences in long-term biodistribution and excretion. Investig Radiol. 2016;51(11):691–700.

    Article  CAS  Google Scholar 

  3. Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging. 2009;30(6):1259–67.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Sherry AD, Caravan P, Lenkinski RE. Primer on gadolinium chemistry. J Magn Reson Imaging. 2009;30(6):1240–8.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Frenzel T, Lengsfeld P, Schirmer H, Hütter J, Weinmann HJ. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Investig Radiol. 2008;43(12):817–28.

    Article  CAS  Google Scholar 

  6. Hao D, Ai T, Goerner F, Hu X, Runge VM, Tweedle M. MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging. 2012;36(5):1060–71.

    Article  PubMed  Google Scholar 

  7. de Kerviler E, Maravilla K, Meder JF, Naggara O, Dubourdieu C, Jullien V, Desché P. Adverse reactions to gadoterate meglumine: review of over 25 years of clinical use and more than 50 million doses. Investig Radiol. 2016;51(9):544–51.

    Article  CAS  Google Scholar 

  8. Endrikat J, Vogtlaender K, Dohanish S, Balzer T, Breuer J. Safety of gadobutrol: results from 42 clinical phase II to IV studies and postmarketing surveillance after 29 million applications. Investig Radiol. 2016;51(9):537–43.

    Article  CAS  Google Scholar 

  9. Endrikat JS, Dohanish S, Balzer T, Breuer JA. Safety of gadoxetate disodium: results from the clinical phase II–III development program and postmarketing surveillance. J Magn Reson Imaging. 2015;42(3):634–43.

    Article  PubMed  Google Scholar 

  10. Forsting M, Palkowitsch P. Prevalence of acute adverse reactions to gadobutrol—a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials. Eur J Radiol. 2010;74(3):e186–92.

    Article  PubMed  Google Scholar 

  11. Wagner B, Drel V, Gorin Y. Pathophysiology of gadolinium-associated systemic fibrosis. Am J Physiol Ren Physiol. 2016;311(1):F1–F11.

    Article  CAS  Google Scholar 

  12. Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals. 2016;29(3):365–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M. Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol. 2016;37(7):1192–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Fretellier N, Poteau N, Factor C, Mayer JF, Medina C, Port M, Idée JM, Corot C. Analytical interference in serum iron determination reveals iron versus gadolinium transmetallation with linear gadolinium-based contrast agents. Investig Radiol. 2014;49(12):766–72.

    Article  CAS  Google Scholar 

  15. Idée JM, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: a critical update. Crit Rev Toxicol. 2014;44(10):895–913.

    Article  PubMed  CAS  Google Scholar 

  16. Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol. 2008;66(2):160–7.

    Article  PubMed  Google Scholar 

  17. Khawaja AZ, Cassidy DB, Al Shakarchi J, McGrogan DG, Inston NG, Jones RG. Revisiting the risks of MRI with gadolinium based contrast agents-review of literature and guidelines. Insights Imaging. 2015;6(5):553–8.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, Thomsen HS. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J. 2012;5(1):82–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Assessment report for Gadolinium-containing contrast agents. EMA/740640/2010. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/gadolinium_31/WC500099538.pdf.

  20. Sanyal S, Marckmann P, Scherer S, Abraham JL. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis—an autopsy-based review. Nephrol Dial Transplant. 2011;26(11):3616–26.

    Article  CAS  PubMed  Google Scholar 

  21. Swaminathan S, High WA, Ranville J, Horn TD, Hiatt K, Thomas M, Brown HH, Shah SV. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int. 2008;73(12):1413–8.

    Article  CAS  PubMed  Google Scholar 

  22. Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270(3):834–41.

    Article  PubMed  Google Scholar 

  23. Errante Y, Cirimele V, Mallio CA, Di Lazzaro V, Zobel BB, Quattrocchi CC. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Investig Radiol. 2014;49(10):685–90.

    Article  CAS  Google Scholar 

  24. Kanda T, Osawa M, Oba H, Toyoda K, Kotoku J, Haruyama T, Takeshita K, Furui S. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology. 2015;275(3):803–9.

    Article  PubMed  Google Scholar 

  25. Quattrocchi CC, Mallio CA, Errante Y, Cirimele V, Carideo L, Ax A, Zobel BB. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Investig Radiol. 2015;50(7):470–2.

    Article  Google Scholar 

  26. Radbruch A, Weberling LD, Kieslich PJ, Eidel O, Burth S, Kickingereder P, Heiland S, Wick W, Schlemmer HP, Bendszus M. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. 2015;275(3):783–91.

    Article  PubMed  Google Scholar 

  27. Ramalho J, Castillo M, AlObaidy M, Nunes RH, Ramalho M, Dale BM, Semelka RC. High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology. 2015;276(3):836–44.

    Article  PubMed  Google Scholar 

  28. Kahn J, Posch H, Steffen IG, Geisel D, Bauknecht C, Liebig T, Denecke T. Is there long-term signal intensity increase in the central nervous system on T1-weighted images after MR imaging with the hepatospecific contrast agent gadoxetic acid? a cross-sectional study in 91 patients. Radiology. 2017;282(3):708–16.

    Article  PubMed  Google Scholar 

  29. Ichikawa S, Motosugi U, Omiya Y, Onishi H. Contrast agent-induced high signal intensity in dentate nucleus on unenhanced T1-weighted images: Comparison of gadodiamide and gadoxetic acid. Invest Radiol. 2017;52(7):389–95.

    Article  CAS  PubMed  Google Scholar 

  30. McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, Williamson EE, Eckel LJ. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275(3):772–82.

    Article  PubMed  Google Scholar 

  31. Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, Haruyama T, Kitajima K, Furui S. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology. 2015;276(1):228–32.

    Article  PubMed  Google Scholar 

  32. Zhang Y, Cao Y, Shih GL, Hecht EM, Prince MR. Extent of signal hyperintensity on unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents. Radiology. 2017;282(2):516–25.

    Article  PubMed  Google Scholar 

  33. Radbruch A, Haase R, Kieslich PJ, Weberling LD, Kickingereder P, Wick W, Schlemmer HP, Bendszus M. No signal intensity increase in the dentate nucleus on unenhanced T1-weighted MR images after more than 20 serial injections of macrocyclic gadolinium-based contrast agents. Radiology. 2017;282(3):699–707.

    Article  PubMed  Google Scholar 

  34. Robert P, Lehericy S, Grand S, Violas X, Fretellier N, Idée JM, Ballet S, Corot C. T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Investig Radiol. 2015;50(8):473–80.

    Article  CAS  Google Scholar 

  35. Robert P, Violas X, Grand S, Lehericy S, Idée JM, Ballet S, Corot C. Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Investig Radiol. 2016;51(2):73–82.

    Article  CAS  Google Scholar 

  36. Rasschaert M, Idée JM, Robert P, Fretellier N, Vives V, Violas X, Ballet S, Corot C. Moderate renal failure accentuates T1 signal enhancement in the deep cerebellar nuclei of gadodiamide-treated rats. Investig Radiol. 2017;52(5):255–64.

    Article  CAS  Google Scholar 

  37. Smith AP, Marino M, Roberts J, Crowder JM, Castle J, Lowery L, Morton C, Hibberd MG, Evans PM. Clearance of gadolinium from the brain with no pathologic effect after repeated administration of gadodiamide in healthy rats: an analytical and histologic study. Radiology. 2017;282(3):743–51.

    Article  PubMed  Google Scholar 

  38. Frenzel T, Apte C, Jost G, Schöckel L, Lohrke J, Pietsch H. Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents: comparative study in rats. Investig Radiol. 2017;52(7):396–404.

    Article  CAS  Google Scholar 

  39. Jost G, Frenzel T, Lohrke J, Lenhard DC, Naganawa S, Pietsch H. Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue. Eur Radiol. 2017;27(7):2877–85.

    Article  PubMed  Google Scholar 

  40. Öner AY, Barutcu B, Aykol Ş, Tali ET. Intrathecal contrast-enhanced magnetic resonance imaging-related brain signal changes: residual gadolinium deposition? Investig Radiol. 2017;52(4):195–7.

    Article  CAS  Google Scholar 

  41. Olchowy C, Cebulski K, Łasecki M, Chaber R, Olchowy A, Kałwak K, Zaleska-Dorobisz U. The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity—a systematic review. PLoS One. 2017;12(2):e0171704.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Vidaud C, Bourgeois D, Meyer D. Bone as target organ for metals: the case of f-elements. Chem Res Toxicol. 2012;25(6):1161–75.

    Article  CAS  PubMed  Google Scholar 

  43. Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Investig Radiol. 2004;39(3):138–42.

    Article  Google Scholar 

  44. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Investig Radiol. 2006;41(3):272–8.

    Article  Google Scholar 

  45. Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Ellen Campbell M, Hauschka PV, Hannigan RE. Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics. 2009;1(6):479–88.

    Article  CAS  PubMed  Google Scholar 

  46. Wáng YX, Schroeder J, Siegmund H, Idée JM, Fretellier N, Jestin-Mayer G, Factor C, Deng M, Kang W, Morcos SK. Total gadolinium tissue deposition and skin structural findings following the administration of structurally different gadolinium chelates in healthy and ovariectomized female rats. Quant Imaging Med Surg. 2015;5(4):534–45.

    PubMed  PubMed Central  Google Scholar 

  47. Murata N, Gonzalez-Cuyar LF, Murata K, Fligner C, Dills R, Hippe D, Maravilla KR. Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Investig Radiol. 2016;51(7):447–53.

    Article  CAS  Google Scholar 

  48. Murata N, Murata K, Gonzalez-Cuyar LF, Maravilla KR. Gadolinium tissue deposition in brain and bone. Magn Reson Imaging. 2016;34(10):1359–65.

    Article  CAS  PubMed  Google Scholar 

  49. Kasokat T, Urich K. Quantification of dechelation of gadopentetate dimeglumine in rats. Arzneimittelforschung. 1992;42(6):869–76.

    CAS  PubMed  Google Scholar 

  50. Wadas TJ, Sherman CD, Miner JH, Duncan JR, Anderson CJ. The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice. Magn Reson Med. 2010;64(5):1274–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008;3(Suppl 3):S131–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Khurana A, Greene JF Jr, High WA. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol. 2008;59(2):218–24.

    Article  PubMed  Google Scholar 

  53. Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR. Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2011;64(1):91–6.

    Article  CAS  PubMed  Google Scholar 

  54. Roberts DR, Lindhorst SM, Welsh CT, Maravilla KR, Herring MN, Braun KA, Thiers BH, Davis WC. High levels of gadolinium deposition in the skin of a patient with normal renal function. Investig Radiol. 2016;51(5):280–9.

    Article  CAS  Google Scholar 

  55. Gathings RM, Reddy R, Santa Cruz D, Brodell RT. Gadolinium-associated plaques: a new, distinctive clinical entity. JAMA Dermatol. 2015;151(3):316–9.

    Article  PubMed  Google Scholar 

  56. Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, Walter J, Weinmann HJ, Pietsch H. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008;18(10):2164–73.

    Article  PubMed  Google Scholar 

  57. Pietsch H, Lengsfeld P, Jost G, Frenzel T, Hütter J, Sieber MA. Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. Eur Radiol. 2009;19(6):1417–24.

    Article  PubMed  Google Scholar 

  58. Maximova N, Gregori M, Zennaro F, Sonzogni A, Simeone R, Zanon D. Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric hematopoietic stem cell transplant recipients. Radiology. 2016;281(2):418–26.

    Article  PubMed  Google Scholar 

  59. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Investig Radiol. 1995;30(6):372–80.

    Article  CAS  Google Scholar 

  60. Chen R, Ling D, Zhao L, Wang S, Liu Y, Bai R, Baik S, Zhao Y, Chen C, Hyeon T. Parallel comparative studies on mouse toxicity of oxide nanoparticle- and gadolinium-based T1 MRI contrast agents. ACS Nano. 2015;9(12):12425–35.

    Article  CAS  PubMed  Google Scholar 

  61. Spencer AJ, Wilson SA, Batchelor J, Reid A, Rees J, Harpur E. Gadolinium chloride toxicity in the rat. Toxicol Pathol. 1997;25(3):245–55.

    Article  CAS  PubMed  Google Scholar 

  62. Kartamihardja AA, Nakajima T, Kameo S, Koyama H, Tsushima Y. Impact of impaired renal function on gadolinium retention after administration of gadolinium-based contrast agents in a mouse model. Investig Radiol. 2016;51(10):655–60.

    Article  CAS  Google Scholar 

  63. Semelka RC, Commander CW, Jay M, Burke LM, Ramalho M. Presumed gadolinium toxicity in subjects with normal renal function: a report of 4 cases. Investig Radiol. 2016;51(10):661–5.

    Article  CAS  Google Scholar 

  64. Burke LM, Ramalho M, AlObaidy M, Chang E, Jay M, Semelka RC. Self-reported gadolinium toxicity: a survey of patients with chronic symptoms. Magn Reson Imaging. 2016;34(8):1078–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diagnostic Imaging, Universita Campus Bio-Medico di Roma, Rome, Italy

    Carlo Cosimo Quattrocchi

  2. Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands

    Aart J. Van Der Molen

Authors
  1. Carlo Cosimo Quattrocchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aart J. Van Der Molen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Carlo Cosimo Quattrocchi or Aart J. Van Der Molen .

Editor information

Editors and Affiliations

  1. Department of Nephrology and Dialysis, “Cannizzaro” Emergency Hospital, Catania, Italy

    Antonio Granata

  2. Department of Radiology, Cattinara Hospital, University of Trieste, Trieste, Italy

    Michele Bertolotto

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Quattrocchi, C.C., Van Der Molen, A.J. (2021). Gadolinium Retention in Brain and Body: Clinical and Preclinical Evidence. In: Granata, A., Bertolotto, M. (eds) Imaging in Nephrology. Springer, Cham. https://doi.org/10.1007/978-3-030-60794-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-60794-4_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-60792-0

  • Online ISBN: 978-3-030-60794-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation